Last update: April 21, 2015

Moclobemide

Very Low Risk for breastfeeding


Safe. Compatible.
Not risky for breastfeeding or infant.

Excreted into breast milk in a clinically non-significant amount.

No clinical untoward effects on the physical and psychomotor development of the infants at both short and long-term basis.

Some reports of galactorrhea have been described.

Because there is less published experience with this drug than with others, an alternative known to be safer should be preferred mostly during the neonatal period or prematurity.

Alternatives

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Group

Moclobemide belongs to this group or family:

Tradenames

Main tradenames from several countries containing Moclobemide in its composition:

Pharmacokinetics

Variable Value Unit
Bioavailability 80 %
Molecular weight 269 daltons
Protein Binding 50 %
VD 1,2 l/Kg
Tmax 1 - 2 hours
T1/2 2 - 4 hours
M/P ratio 0,7 -
Theoretical Dose 0,2 - 0,8 mg/Kg/d
Relative Dose 2,5 - 5,3 %

References

  1. MHRA. Moclobemide. Drug Summary. 2014 Full text (in our servers)
  2. AEMPS. Moclobemida. Ficha técnica. 2011 Full text (in our servers)
  3. Taylor T, Kennedy D. Safety of moclobemide in pregnancy and lactation, four case reports. Birth Defects Research Part A- Clinical and Molecular Teratology. 2008;82:413. 2008
  4. Dunn NR, Freemantle SN, Pearce GL, Mann RD. Galactorrhoea with moclobemide. Lancet. 1998 Abstract
  5. Håberg M, Matheson I. [Antidepressive agents and breast feeding]. Tidsskr Nor Laegeforen. 1997 Abstract
  6. Juruena MF, Pires ML, Calil HM. Moclobemide effects on prolactin plasma levels in healthy individuals: the hormonal increase induced by a single dose is maintained during a 4-week period of drug intake. Int Clin Psychopharmacol. 1997 Abstract
  7. Nair NP, Ahmed SK, Kin NM. Biochemistry and pharmacology of reversible inhibitors of MAO-A agents: focus on moclobemide. J Psychiatry Neurosci. 1993 Abstract Full text (link to original source) Full text (in our servers)
  8. Pons G, Schoerlin MP, Tam YK, Moran C, Pfefen JP, Francoual C, Pedarriosse AM, Chavinie J, Olive G. Moclobemide excretion in human breast milk. Br J Clin Pharmacol. 1990 Abstract Full text (link to original source) Full text (in our servers)

Total visits

3,267

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine from United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM